Ampersand Biomedicines is a Boston, MA-based multi-product platform company developing smart medicines. Its computationally empowered Address, Navigate, Determine (AND)™ platform identifies ideal addresses for drug localization and informs the design of AND-Body™ Therapeutics. AND-Body Therapeutics are designed to localize to intended targets and conditionally actuate biology to treat disease, enabling improved target engagement while limiting on-target, off-tissue side effects. The company raised $65M in Series B financing from backers that include Ampersand’s founder, Flagship Pioneering, Eli Lilly & Company and additional new investors to accelerate its initial pipeline. Its initial programs include candidates in immuno-inflammation and immuno-oncology, both planned to enter IND-enabling studies in 2025. The company is led by CEO Jason Gardner. Ampersand Biomedicines developed an Address, Navigate, Design (AND) platform that analyzes RNA transcript data across the human body to find disease-specific molecular "addresses" for targeting drugs. The company pairs a "localizer" that binds an address with an "actuator" carrying therapeutic effect, and actuators can be small molecules, proteins, lipid nanoparticles, or nucleic acids. Ampersand has generated or acquired transcriptomic datasets, validated its address map in multiple preclinical tests, and is conducting animal testing to further validate localization and therapeutic activity. The startup emerged from stealth as it progresses toward human testing and plans to expand headcount (currently 33 employees). Founded within Flagship Pioneering's lab incubator in 2020, Ampersand is positioned to pursue partnerships where larger companies may use its technology or develop drugs originating from its platform. The company aims to address on-target, off-tissue toxicity and to enable therapies against targets previously considered undruggable due to promiscuous biodistribution.

Total raised

$115M

Funding rounds

2

Latest round

Series B

Latest activity

Mar 2025